Eliprodil, >=98% (HPLC), powder

Code: e2031-10mg D2-231

Not available outside of the UK & Ireland.

Biochem/physiol Actions

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B ...


 Read more

Your Price
$207.31 10MG
REQUEST

Not available outside of the UK & Ireland.

Biochem/physiol Actions

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

10, 50 mg in glass bottle

assay≥98% (HPLC)
colorwhite to beige
formpowder
Gene Informationhuman ... GRIN2B(2904)rat ... Adra1a(29412)
InChI keyGGUSQTSTQSHJAH-UHFFFAOYSA-N
InChI1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
originatorSanofi Aventis
SMILES stringOC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3
solubilityDMSO: 5 mg/mL, clear, H2O: insoluble
storage temp.2-8°C
Cas Number119431-25-3
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN
GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.